Long-term legacy effects and cost-effectiveness still discussed in context of 2026 aggressive lipid lowering trials and new guidelines.
Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
Does alirocumab reduce recurrent ischemic cardiovascular events in patients with previous acute coronary syndrome receiving high-intensity statin therapy?
Patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy
Alirocumab
Placebo
Recurrent ischemic cardiovascular eventshard clinical
Alirocumab reduces the risk of recurrent ischemic cardiovascular events in patients with a history of acute coronary syndrome on background high-intensity statin therapy.
Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Gregory G. Schwartz
Philippe Gabríel Steg
Michael Szarek
New England Journal of Medicine
Harvard University
Stanford University
University of Toronto
Building similarity graph...
Analyzing shared references across papers
Loading...
Schwartz et al. (Wed,) reported a other. Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
www.synapsesocial.com/papers/698cdf111796157a23493cb0 — DOI: https://doi.org/10.1056/nejmoa1801174
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: